Comité de Recherche Direction

Name

Role

Richard HawkesChairBio
Dr. Hawkes' research focuses on spatially repeated patterns in developing organisms, such as the mammalian cerebellum. Zebrins are expressed in the adult mouse cerebellum in an array of stripes, which correlates closely with the pattern of axons bringing information into the cerebellum. We explore how zebrin bands are generated, how the different ingrowing axons recognize their appropriate targets, what the modular structure of the cerebellum is and how cerebellar modules function in motor control. Dr. Hawkes uses cell and molecular biology techniques including monoclonal antibodies to zebrins, cloning zebrin genes and constructing zebrin transgenic mice, immunocytochemistry, and in situ hybridization, surgical and pharmacological interventions, and culture of cerebellar slices and dissociated neurons.
Julia AlleyneMemberBio
Dr. Julia Alleyne is a Family Physician practicing sport and exercise medicine . She initially trained as a physiotherapist and held an active license for 30 years. She practices at the Toronto Rehabilitation Institute at the University Health Network as the MSK lead for Outpatient services. Prior to this, she was the Medical Director of Sport C.A.R.E. at Women’s College Hospital. She holds academic appointments with the University of Toronto (UT), Department of Family and Community Medicine. Dr. Alleyne holds a M.Sc. (Community Health) from UT with a focus on Health Practitioner Teacher Education. Dr. Alleyne is the PGY3 Fellowship Director for Sport Medicine at UT and chair the National Sport Medicine Fellowship Directors Committee, the Canadian Academy of Sport Medicine.
Mark BiedaMemberBio
Dr. Bieda's overall research areas are in bioinformatics and epigenetics. He is particularly interested in roles of epigenetic modifications in controlling processes in neuroscience and cancer. Here, Dr. Bieda uses epigenetics in the “modern” sense (some would say incorrect sense) to refer to modifications of DNA and histones to control gene expression. He’d add in transcription factors here, too, with the risk of diluting epigenetic to just mean “transcriptional regulation”.
Jim BrienMemberBio
James F. Brien is Professor of Pharmacology and Toxicology in the School of Medicine at Queen's University. He has an active, multi-faceted research program in pharmacology and toxicology that, for over 25 years, has focused primarily on Fetal Alcohol Syndrome (FAS) / Fetal Alcohol Spectrum Disorders (FASD), with particular emphasis on the brain injury of FAS / FASD. His research program has been funded continuously by the Canadian Institutes of Health Research (CIHR) and the former Medical Research Council of Canada. He has been involved in several functions of CIHR, including multidisciplinary and transdisciplinary peer-review committees, and University Delegate at Queen’s. Currently, he is a member of the CIHR Governing Council.
Chris FibigerMemberBio
H. Christian Fibiger, Ph.D. received his B.Sc. in Chemistry and Psychology from the University of Victoria in 1966 and his Ph.D. in Psychopharmacology from Princeton University in 1970. Dr. Fibiger was formerly the Chief Scientific Officer for Biovail Laboratories International (now Valeant). From 2003 until 2007 he was Vice President and Global Head of Neuroscience at Amgen. In this position he was responsible for Amgen’s worldwide Neuroscience discovery efforts ranging from early exploratory research through clinical candidate selection. Before joining Amgen in 2003, Dr. Fibiger served as Vice President of Neuroscience Discovery Research and Clinical Investigation, and LRL Europe at Eli Lilly and Company. Before moving to Lilly in 1998, Dr. Fibiger served as Professor and Head of the Division of Neurological Sciences and Chair of the University Graduate Program in Neuroscience at the University of British Columbia in Vancouver. He has made numerous contributions to neuroscience research and, during his academic career, was among the top 100 most cited scientists in neuroscience. He has received many honors for his research contributions, including the Clark Institute Prize in Psychiatry, the Heinz Lehmann Award of the Canadian College of Neuropsychopharmacology, the Killam Research Prize, the Gold Medal in Health Sciences from the Science Council of British Columbia and the Tanenbaum Distinguished Scientist Award in Schizophrenia Research. He is a Fellow of the American College of Neuropsychopharmacology (ACNP). Dr. Fibiger serves on the editorial boards of several journals in the field of neuroscience and has been coeditor of Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology.
Jan FriedmanMemberBio
Dr. Friedman’s research bridges clinical genetics and basic science. Our work is focused in three major areas. The first area involves application of advanced genomic technology to identifying the causes of mental retardation. The second area uses genetic epidemiology - statistical analysis of large collections of clinical and genetic data and various other methods - to understand the disease processes in people with neurofibromatosis, a common genetic condition that leads to the development of benign and malignant tumours, cardiovascular disease and osteoporosis. The third area examines development and dissemination of authoritative information on human teratogenic risks (risks to embryonic or fetal development) resulting from maternal treatment with various medications during pregnancy.
Daniel GoldowitzMemberBio
Dan Goldowitz received his PhD in Psychobiology at the University of California at Irvine with a thesis that focused on the plasticity of the adult central nervous in response to lesions. His subsequent postdoctoral work at Harvard Children’s Hospital in Boston, the Karolinska Institute in Stockholm, and the University of Utah School of Medicine in Salt Lake City was in the development of the nervous system. His first position was as an assistant professorship at Jefferson Medical School in Philadelphia. Using approaches that were relatively novel to the study of the brain he pioneered approaches to ascertain the function of genes in brain and behaviour. He moved to the University of Tennessee Health Science Centre (UTHSC) in Memphis and was a leading force in organizing researchers across the State of Tennessee in forming a collaborative to use the mouse as a model organism to identify the function of the genes that were just being uncovered with the human genome project. The Tennessee Mouse Genome Consortium was the result of these efforts and this collaborative won one of three US National Institute’s of Health (NIH) awards (amounting to about US$13,000,000 over 5years with D. Goldowitz as the Principal Investigator) to understand the role of genes in the function of the brain. This success led the University of Tennessee system to create a US$6,000,000 in a program to fund a Centre of Excellence in Genomics and Bioinformatics proposed by Goldowitz. He also worked with other individuals at UTHSC to obtain NIH funding for projects to bring science education to the K-12 grades. He was awarded an endowed chair of Neurosciences at UTHSC. These efforts have resulted in national and international collaborations that Dan brought to Canada (the Centre for Molecular Medicine and Therapeutics at the Children and Family Research Inst at UBC). He currently holds a Tier 1 Canada Research Chair. He maintains strong NIH- , CIHR- and foundation-funded research programs in the genetics of brain development and function. After a bit more than one year in Canada the call for proposals from the Networks of Centres of Excellence (NCE) was published. A survey of the research landscape indicated that Canada had some incredible strength in brain development, both clinically and in the basic sciences, but that they were not united in a way that could bring a synergy that seemed possible. From this as a vantage point, and with a focus of creating a marriage between the clinical and basic sciences, Goldowitz led a successful application to be one of three new, federally funded NCEs, NeuroDevNet.
Mary JohnstonMemberBio
A graduate of University of Guelph and University of Toronto, Professional Home Economist and former teacher, Mary worked in Health Canada and Public Health Agency in diverse positions since 1980. Since 1987, Mary applied her skills to research and knowledge development for promotion of health for children (0 to 18). From 1997 until 2002 as Senior Research Analyst, Division of Childhood and Adolescence she was noted for innovation in translating and disseminating research findings to transform policy, program and practice. Since 2002, Mary managed the FASD Initiative within the PHAC. The focus has been on prevention of future alcohol affected births, improvement of outcomes for those affected and development of prevalence and cost data for Canada.
Bryan KolbMemberBio
Dr. Kolb combines neuroscience and psychology to examine the important interplay between experiences, neuron changes and behaviour. His research has focused on the cerebral cortex and how neurons change in response to experiences, drugs, hormones and injury, which in turn affect behaviour. In discovering factors affecting the cerebral cortex in an embryo as well as during the early years of development, he and his research team were able to plot strategies for improving recovery from early brain injury and precautions for pregnant mothers. His research has spurred new treatments to help patients with Alzheimer’s Disease, stroke, or afflicted by drug abuse or head injuries.
Lucy OsborneMember, Ex-OfficioBio
Dr. Osborne received her PhD from The University of London, England (1993) and completed post-doctoral training in human genetics with Prof. Lap-Chee Tsui at the Hospital for Sick Children, Toronto. She was appointed at the University of Toronto in 1999 and is currently a Professor in the departments of Medicine and Molecular Genetics. The major focus of Dr. Osborne’s research is chromosome rearrangements of human chromosome 7q11.23, with the aim of understanding the molecular basis of the resulting neurodevelopmental disorders. Her lab is at the forefront of research into the deletion disorder Williams syndrome, as well as it’s reciprocal duplication disorder, and has helped elucidate the range of complex chromosomal rearrangements associated with this part of chromosome 7. Her team are currently using both human participants and animal models to probe the molecular and cellular bases of cognitive and behavioural aspects of these syndromes with the long term goal of developing targeted therapeutic options. Dr. Osborne is currently chair of the NeuroDevNet Research Training Committee.
James ReynoldsMember, Ex-OfficioBio
Dr. James Reynolds is a graduate of Queen’s University (B.Sc., 1982, Ph.D, 1987). His thesis research investigated the neurochemical mechanisms underlying heavy metal toxicity. Subsequently, he completed postdoctoral training at the Addiction Research Foundation and the University of Toronto. Dr. Reynolds’ first faculty position was at Memorial University in St. John's, Newfoundland. He returned to Queen's in 1995, where his research program has grown to encompass both basic and clinical investigations. Dr. Reynolds is a Full Professor in the Department of Biomedical and Molecular Sciences, and the Centre for Neuroscience Studies, at Queen's University. His research interests over the past 20 years have centred around studies on the effects of alcohol on brain function. In particular, his current research program is focused on understanding the mechanisms of brain injury, and the resulting behavioural and cognitive deficits, that are induced by prenatal exposure to alcohol. The long term goal is to understand how prenatal exposure to alcohol alters brain neurochemistry and structure, and thus brain function, in offspring. Dr. Reynolds has been funded by CIHR for interdisciplinary basic and clinical investigations into the cellular mechanisms and neurobehavioural consequences of Fetal Alcohol Spectrum Disorder (FASD). He led a 7-member CIHR-funded New Emerging Team in FASD research, and is the Project Lead for the FASD Demonstration Project in NeuroDevNet.
Vivien SymingtonMemberBio
Vivien is a graduate of Queen’s University where she completed her B.A./B.P.H.E before carrying on to study in the MSC program at Dalhousie University. Vivien was a faculty member both at Queen’s U and Dalhousie U where she was responsible for the gymnastics courses. Vivien minored in Adapted Physical Education and has worked extensively on developing motor skill acquisition programs for children of all abilities. She has 45 plus years of gymnastics coaching experience and 30 years experience as a gymnastics business owner founding and operating Club Aviva Recreation Ltd. Club Aviva is a large community-based gymnastics centre which offers a wide range of recreational, competitive and specialized programs. In 2002 she founded the Empowering Steps Movement Therapy Program (ESMT) which now treats over 130 children with a wide range of neurodevelopmental disabilities per week. The program is based upon 15 years of research and practical knowledge reflecting her philosophy of promoting optimal motor, social and emotional development for all children and youth, regardless of their level of ability or disability.
Laura WilliamsMemberBio

Information to come soon